TR200102985T2 - Gen tedavisi teknikleri. - Google Patents

Gen tedavisi teknikleri.

Info

Publication number
TR200102985T2
TR200102985T2 TR2001/02985T TR200102985T TR200102985T2 TR 200102985 T2 TR200102985 T2 TR 200102985T2 TR 2001/02985 T TR2001/02985 T TR 2001/02985T TR 200102985 T TR200102985 T TR 200102985T TR 200102985 T2 TR200102985 T2 TR 200102985T2
Authority
TR
Turkey
Prior art keywords
gene therapy
egr
wounds
nucleic acid
treatment
Prior art date
Application number
TR2001/02985T
Other languages
English (en)
Inventor
Braddock Martin
Jeffrey Campbell Callum
Schwachtgen Jean-Lue
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9811836.7A external-priority patent/GB9811836D0/en
Priority claimed from GBGB9815035.2A external-priority patent/GB9815035D0/en
Priority claimed from GBGB9819846.8A external-priority patent/GB9819846D0/en
Priority claimed from GBGB9828578.6A external-priority patent/GB9828578D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200102985T2 publication Critical patent/TR200102985T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Bulus, insanlar dahil bir memelide yaralarin tedavisi için bir ilacin üretiminde, bir Egr-1 transkripsiyon faktörü polipeptidinin veya bunun biyolojik olarak aktif bir fregmaninin kullanimi ile, bu tip polipeptitleri sifreleyen nükleikasit molekülleri ile ilgilidir. Ek olarak, bulus, insanlarda Egr-1 transkripsiyon fakktörünün transkripsiyonunda ve bunun düzenlenmesinde yer alan önemli bölgeleri içerdigi kabul edilen bir dizi ilgilidir. Bu dizi yaralarin tedavisnde, ve ayni zamanda diger tedavilerde kullanilabilen uygun nükleik asit moleküllerini ve vektörlerini tasarlamak için kullanilabilir.
TR2001/02985T 1998-06-02 1999-06-02 Gen tedavisi teknikleri. TR200102985T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9811836.7A GB9811836D0 (en) 1998-06-02 1998-06-02 Gene therapy method
GBGB9815035.2A GB9815035D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819846.8A GB9819846D0 (en) 1998-09-12 1998-09-12 Gene therapy method
GBGB9828578.6A GB9828578D0 (en) 1998-12-23 1998-12-23 Regulation

Publications (1)

Publication Number Publication Date
TR200102985T2 true TR200102985T2 (tr) 2002-06-21

Family

ID=27451790

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/02985T TR200102985T2 (tr) 1998-06-02 1999-06-02 Gen tedavisi teknikleri.
TR2001/00348T TR200100348T2 (tr) 1998-06-02 1999-06-02 Gen tedavisi teknikleri

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/00348T TR200100348T2 (tr) 1998-06-02 1999-06-02 Gen tedavisi teknikleri

Country Status (29)

Country Link
US (1) US6689758B1 (tr)
EP (2) EP1281763A3 (tr)
JP (1) JP2002516676A (tr)
KR (1) KR20010043968A (tr)
CN (1) CN1311822A (tr)
AP (1) AP2000001999A0 (tr)
AT (1) ATE246518T1 (tr)
AU (1) AU770497B2 (tr)
BR (1) BR9910877A (tr)
CA (1) CA2334171A1 (tr)
DE (1) DE69910202T2 (tr)
DK (1) DK1083934T3 (tr)
EA (1) EA200001124A1 (tr)
EE (1) EE200000790A (tr)
ES (1) ES2205830T3 (tr)
HK (1) HK1034465A1 (tr)
HR (1) HRP20000832A2 (tr)
HU (1) HUP0103252A3 (tr)
ID (1) ID27483A (tr)
IL (1) IL139936A0 (tr)
IS (1) IS5742A (tr)
NO (1) NO20006047L (tr)
NZ (1) NZ508505A (tr)
PL (1) PL345207A1 (tr)
PT (1) PT1083934E (tr)
SK (1) SK18322000A3 (tr)
TR (2) TR200102985T2 (tr)
WO (1) WO1999062561A2 (tr)
YU (1) YU75600A (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
EP1467207B1 (en) * 2002-01-10 2008-06-04 Takeda Pharmaceutical Company Limited Screening method for a prophylactic and therapeutic substance for a renal disease.
CA2511315A1 (en) * 2002-12-31 2004-07-22 The Johns Hopkins University Wound healing method and kits
JPWO2005021045A1 (ja) * 2003-08-29 2006-10-26 アンジェスＭｇ株式会社 針無注射器を用いた皮膚疾患の遺伝子治療
DE10342071B4 (de) * 2003-09-10 2006-01-19 Fleischmann, Wilhelm, Dr.med. Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche
KR100647490B1 (ko) 2004-10-04 2006-11-23 사회복지법인 삼성생명공익재단 저산소 조건 및 다른 스트레스에 특이적으로 반응할 수있는 키메라 인핸서 요소를 포함하는 벡터, 상기 벡터를포함하는 약제학적 조성물 및 상기 조성물을 이용하는 방법
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
FR2920158B1 (fr) * 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
FR2924128A1 (fr) * 2007-11-26 2009-05-29 Galderma Res & Dev Modulateurs de egr1 dans le traitement de l'alopecie
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
CN102552938A (zh) * 2012-03-22 2012-07-11 南京大学 Egr-1拮抗剂在制备治疗Ⅱ型糖尿病的药物中的用途
EP2846839B1 (en) 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
KR101721228B1 (ko) * 2015-04-03 2017-03-30 사회복지법인 삼성생명공익재단 지방유래 줄기세포의 배양액을 유효성분으로 포함하는 발모촉진용 조성물
CN104857529A (zh) * 2015-05-20 2015-08-26 山西大学 Egr-1基因在制备抗膀胱癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
AUPN855496A0 (en) * 1996-03-07 1996-04-04 Unisearch Limited Prevention of proliferation of vascular cells

Also Published As

Publication number Publication date
ID27483A (id) 2001-04-12
YU75600A (sh) 2004-03-12
SK18322000A3 (sk) 2001-11-06
HUP0103252A3 (en) 2003-09-29
HRP20000832A2 (en) 2001-04-30
HUP0103252A2 (hu) 2001-12-28
NO20006047L (no) 2001-02-01
US6689758B1 (en) 2004-02-10
EP1083934B1 (en) 2003-08-06
DK1083934T3 (da) 2003-12-01
NO20006047D0 (no) 2000-11-29
AU770497B2 (en) 2004-02-26
ES2205830T3 (es) 2004-05-01
AU4156099A (en) 1999-12-20
PT1083934E (pt) 2003-12-31
IL139936A0 (en) 2002-02-10
NZ508505A (en) 2003-04-29
EP1083934A2 (en) 2001-03-21
EP1281763A2 (en) 2003-02-05
DE69910202D1 (de) 2003-09-11
BR9910877A (pt) 2002-01-22
IS5742A (is) 2000-11-28
WO1999062561A3 (en) 2000-08-03
AP2000001999A0 (en) 2000-12-31
ATE246518T1 (de) 2003-08-15
TR200100348T2 (tr) 2001-07-23
JP2002516676A (ja) 2002-06-11
PL345207A1 (en) 2001-12-03
KR20010043968A (ko) 2001-05-25
DE69910202T2 (de) 2004-06-17
HK1034465A1 (en) 2001-10-26
EA200001124A1 (ru) 2001-08-27
CN1311822A (zh) 2001-09-05
WO1999062561A2 (en) 1999-12-09
EE200000790A (et) 2002-04-15
EP1281763A3 (en) 2003-07-09
CA2334171A1 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
TR200102985T2 (tr) Gen tedavisi teknikleri.
DE69637147D1 (de) Transportproteine und deren verwendungen
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
DE69837754D1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
CY1109926T1 (el) Τροποποιημενο νουκλεϊκο οξυ και φορεις εκφρασης cea
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
NO20014537L (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
BR0014740A (pt) Lantibiótico
DE602004008791D1 (de) Abgabe von genetischem matieral an eine stimulationsstelle
ATE407217T1 (de) Hochexpression und herstellung von recombinanter s-adenosyl homocysteinase mit hochspezifischer aktivität und verbesserte testverfahren für s- adenosylmethionine (sam)
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
TR199700842T1 (tr) Insan DNase I Varyantlari.
DK0811068T3 (da) Humane DNase I varianter
DE60034874D1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
YU1901A (sh) Upotreba nab1 i nab2 u farmaciji
ATE335080T1 (de) Rekombinante proteine abgeleitet von hgf und msp
ATE309354T1 (de) Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen
DE60024442D1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie